US6458772B1
(en)
*
|
1909-10-07 |
2002-10-01 |
Medivir Ab |
Prodrugs
|
DE3623397A1
(de)
*
|
1986-07-11 |
1988-01-14 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
EP0317505A1
(de)
*
|
1987-11-13 |
1989-05-24 |
Ciba-Geigy Ag |
Neue Azacycloalkylalkandiphosphonsäuren
|
EP0320455B1
(de)
*
|
1987-12-11 |
1993-06-09 |
Ciba-Geigy Ag |
Araliphatylaminoalkandiphosphonsäuren
|
US5190930A
(en)
*
|
1987-12-11 |
1993-03-02 |
Ciba-Geigy Corporation |
Araliphatylaminoalkanediphosphonic acids
|
US5110807A
(en)
*
|
1988-12-01 |
1992-05-05 |
Ciba-Geigy Corporation |
Araliphatylaminoalkanediphosphonic acids
|
JPH07629B2
(ja)
*
|
1988-01-20 |
1995-01-11 |
山之内製薬株式会社 |
(シクロアルキルアミノ)メチレンビス(フォスフォン酸)および該化合物を有効成分とする医薬
|
US4933472A
(en)
*
|
1988-04-08 |
1990-06-12 |
Yamanouchi Pharmaceutical Co., Ltd. |
Substituted aminomethylenebis(phosphonic acid) derivatives
|
DE3822650A1
(de)
*
|
1988-07-05 |
1990-02-01 |
Boehringer Mannheim Gmbh |
Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
|
RU2091311C1
(ru)
*
|
1988-11-01 |
1997-09-27 |
Арч Дивелопмент Корпорейшн |
Способ извлечения ионов металла
|
GB8825589D0
(en)
*
|
1988-11-02 |
1988-12-07 |
Albright & Wilson |
Purification
|
TW198039B
(da)
*
|
1988-11-28 |
1993-01-11 |
Ciba Geigy Ag |
|
US5154843A
(en)
*
|
1989-02-08 |
1992-10-13 |
The Lubrizol Corporation |
Hydroxyalkane phosphonic acids and derivatives thereof and lubricants containing the same
|
PH26923A
(en)
*
|
1989-03-08 |
1992-12-03 |
Ciba Geigy |
N-substituted amino alkanediphosphonic acids
|
US4987767A
(en)
*
|
1989-06-09 |
1991-01-29 |
Research Corporation Technologies, Inc. |
Exposive detection screening system
|
MX21453A
(es)
*
|
1989-07-07 |
1994-01-31 |
Ciba Geigy Ag |
Preparaciones farmaceuticas que se administran en forma topica.
|
MX21452A
(es)
*
|
1989-07-07 |
1994-01-31 |
Ciba Geigy Ag |
Preparaciones farmaceuticas que se administran en forma topica.
|
US5139786A
(en)
*
|
1989-07-07 |
1992-08-18 |
Ciba-Geigy Corporation |
Topical formulations
|
US5487897A
(en)
|
1989-07-24 |
1996-01-30 |
Atrix Laboratories, Inc. |
Biodegradable implant precursor
|
US5324519A
(en)
*
|
1989-07-24 |
1994-06-28 |
Atrix Laboratories, Inc. |
Biodegradable polymer composition
|
EP0416689B1
(en)
*
|
1989-09-06 |
1995-11-29 |
Merck & Co. Inc. |
Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
|
US5356887A
(en)
*
|
1990-01-31 |
1994-10-18 |
Merck & Co., Inc. |
Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
|
FI89364C
(fi)
*
|
1990-12-20 |
1993-09-27 |
Leiras Oy |
Foerfarande foer framstaellning av nya, farmakologiskt anvaendbara metylenbisfosfonsyraderivat
|
IT1244698B
(it)
*
|
1991-02-01 |
1994-08-08 |
Gentili Ist Spa |
Acidi aril-o arilalchil-acil ammino-alchil-idrossidifosfonici, procedimento per la loro preparazione e loro uso in terapia osteo-articolare e dei tessuti connettori in generale
|
JPH06508365A
(ja)
*
|
1991-06-19 |
1994-09-22 |
ジ・アップジョン・カンパニー |
抗炎症剤としてのりん酸ジアルキル(ジアルコキシホスフィニル)メチル類
|
IT1247034B
(it)
*
|
1991-06-26 |
1994-12-12 |
Gentili Ist Spa |
Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
|
ATE147396T1
(de)
*
|
1991-08-27 |
1997-01-15 |
Ciba Geigy Ag |
N-substituierte aminomethandiphosphonsäuren
|
EP0541037A3
(en)
*
|
1991-11-06 |
1997-02-26 |
Takeda Chemical Industries Ltd |
Squalene synthetase inhibitory composition and use thereof
|
DE4228552A1
(de)
*
|
1992-08-27 |
1994-03-03 |
Boehringer Mannheim Gmbh |
Diphosphonsäuren und deren Salze enthaltende Arzneimittel
|
EP0600834A1
(en)
*
|
1992-11-30 |
1994-06-08 |
Ciba-Geigy Ag |
Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
|
AU670337B2
(en)
|
1992-11-30 |
1996-07-11 |
Novartis Ag |
Use of certain methanebisphosphonic acid derivatives in fracture healing
|
EP0600371B1
(de)
*
|
1992-12-02 |
1999-02-03 |
Hoechst Aktiengesellschaft |
Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
|
US5358941A
(en)
*
|
1992-12-02 |
1994-10-25 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids with lactose
|
US6406714B1
(en)
|
1992-12-02 |
2002-06-18 |
Merck & Co., Inc. |
Dry mix formulation for bisphosphonic acids
|
US6399592B1
(en)
|
1992-12-23 |
2002-06-04 |
Merck & Co., Inc. |
Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
|
CA2151240A1
(en)
*
|
1992-12-23 |
1994-07-07 |
Donna T. Whiteford |
Biophosphonate/estrogen therapy for treating and preventing bone loss
|
TW401276B
(en)
*
|
1993-10-07 |
2000-08-11 |
Zeneca Ltd |
Novel compounds and a method of controlling growth of plants
|
US5728650A
(en)
*
|
1993-10-07 |
1998-03-17 |
Zeneca Limited |
Herbicidal aza bisphosphonic acids and compositions containing the same
|
US5591730A
(en)
*
|
1993-10-12 |
1997-01-07 |
The Regents Of The University Of California |
Inhibition of urinary calculi growth
|
US5681873A
(en)
*
|
1993-10-14 |
1997-10-28 |
Atrix Laboratories, Inc. |
Biodegradable polymeric composition
|
US20010007863A1
(en)
*
|
1998-06-18 |
2001-07-12 |
Merck & Co., Inc. |
Wet granulation formulation for bisphosphonic acids
|
US5780455A
(en)
*
|
1994-08-24 |
1998-07-14 |
Merck & Co., Inc. |
Intravenous alendronate formulations
|
WO1996039107A1
(en)
|
1995-06-06 |
1996-12-12 |
Merck & Co., Inc. |
Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
|
EP0753523A1
(en)
*
|
1995-07-10 |
1997-01-15 |
Gador S.A. |
Amino-substituted bisphosphonic acids
|
AU7213196A
(en)
*
|
1995-09-29 |
1997-04-28 |
Ciba-Geigy Ag |
Method of treating the navicular disease in horses
|
GB9607945D0
(en)
*
|
1996-04-17 |
1996-06-19 |
Univ Nottingham |
Bisphosponates as Anti-inflammatory agents
|
DE19615812A1
(de)
*
|
1996-04-20 |
1997-10-23 |
Boehringer Mannheim Gmbh |
Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
|
KR100192215B1
(ko)
*
|
1996-09-03 |
1999-06-15 |
강재헌 |
3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
|
DE19719680A1
(de)
|
1997-05-09 |
1998-11-19 |
Boehringer Mannheim Gmbh |
Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
US6432932B1
(en)
|
1997-07-22 |
2002-08-13 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US5994329A
(en)
|
1997-07-22 |
1999-11-30 |
Merck & Co., Inc. |
Method for inhibiting bone resorption
|
US6187329B1
(en)
|
1997-12-23 |
2001-02-13 |
Board Of Regents Of The University Of Texas System |
Variable permeability bone implants, methods for their preparation and use
|
US6255359B1
(en)
|
1997-12-23 |
2001-07-03 |
Board Of Regents Of The University Of Texas System |
Permeable compositions and methods for their preparation
|
CN1061661C
(zh)
*
|
1997-12-24 |
2001-02-07 |
国家医药管理局上海医药工业研究院 |
(环庚基胺基)亚甲基二膦酸二钠一水合物制备方法
|
US20020128301A1
(en)
*
|
1998-02-13 |
2002-09-12 |
Medivir AB |
Non-nucleoside reverse transcriptase inhibitors
|
ES2359973T3
(es)
*
|
1998-03-19 |
2011-05-30 |
MERCK SHARP & DOHME CORP. |
Composiciones poliméricas líquidas para la liberación controlada de sustancias bioactivas.
|
US7128927B1
(en)
|
1998-04-14 |
2006-10-31 |
Qlt Usa, Inc. |
Emulsions for in-situ delivery systems
|
EP0998932A1
(de)
|
1998-10-09 |
2000-05-10 |
Boehringer Mannheim Gmbh |
Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
|
EP0998933A1
(de)
|
1998-10-09 |
2000-05-10 |
Boehringer Mannheim Gmbh |
Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
|
PT1135140E
(pt)
|
1998-12-04 |
2005-10-31 |
Roche Diagnostics Gmbh |
Utilizacao de ibandronato para a promocao da integracao ossea de endoproteses
|
WO2000071104A2
(en)
*
|
1999-05-21 |
2000-11-30 |
Novartis Ag |
Use of bisphosphonic acids for treating angiogenesis
|
AR024462A1
(es)
|
1999-07-01 |
2002-10-02 |
Merck & Co Inc |
Tabletas farmaceuticas
|
US8226598B2
(en)
*
|
1999-09-24 |
2012-07-24 |
Tolmar Therapeutics, Inc. |
Coupling syringe system and methods for obtaining a mixed composition
|
AR021347A1
(es)
|
1999-10-20 |
2002-07-17 |
Cipla Ltd |
Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
|
US6677320B2
(en)
|
2000-01-20 |
2004-01-13 |
Hoffmann-La Roches Inc. |
Parenteral bisphosphonate composition with improved local tolerance
|
US6410520B2
(en)
|
2000-02-01 |
2002-06-25 |
The Procter & Gamble Company |
Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
|
US6562974B2
(en)
|
2000-02-01 |
2003-05-13 |
The Procter & Gamble Company |
Process for making geminal bisphosphonates
|
SE0000382D0
(sv)
|
2000-02-07 |
2000-02-07 |
Astrazeneca Ab |
New process
|
WO2001085217A1
(en)
|
2000-05-05 |
2001-11-15 |
F. Hoffmann-La Roche Ag |
Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
US20050070504A1
(en)
*
|
2001-12-21 |
2005-03-31 |
The Procter & Gamble Co. |
Risedronate compositions and their methods of use
|
CN100479823C
(zh)
*
|
2001-12-21 |
2009-04-22 |
宝洁公司 |
双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
|
AU2002364051A1
(en)
*
|
2002-01-24 |
2003-09-02 |
Children's Medical Center Corporation |
Anti-cancer combination and use thereof
|
AU2003226148A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Merck & Co., Inc. |
Method for inhibiting bone resorption with an alendronate and vitamin d formulation
|
ES2532393T3
(es)
*
|
2002-05-10 |
2015-03-26 |
F. Hoffmann-La Roche Ag |
Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
|
US7038083B2
(en)
*
|
2002-05-17 |
2006-05-02 |
Teva Pharmaceutical Industries, Ltd. |
Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons
|
EP1513523A1
(en)
*
|
2002-06-06 |
2005-03-16 |
Merck Frosst Canada & Co. |
1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
|
JP2006504679A
(ja)
*
|
2002-08-28 |
2006-02-09 |
メルク フロスト カナダ アンド カンパニー |
緑内障の治療においてep4受容体作動薬として使用するためのオキサゾリジン−2−オンおよびチアゾリジン−2−オン誘導体
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
US20040097468A1
(en)
*
|
2002-11-20 |
2004-05-20 |
Wimalawansa Sunil J. |
Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
|
NZ536273A
(en)
|
2002-12-20 |
2007-08-31 |
Hoffmann La Roche |
High dose ibandronate formulation
|
ATE402942T1
(de)
*
|
2003-01-17 |
2008-08-15 |
Teva Pharma |
Verfahren zur reduzierung des eisengehalts bei risedronat natrium
|
DE602004024545D1
(de)
*
|
2003-08-21 |
2010-01-21 |
Sun Pharmaceuticals Ind Ltd |
Indungen
|
CA2535359A1
(en)
|
2003-08-21 |
2005-03-03 |
Merck Frosst Canada Ltd. |
Cathepsin cysteine protease inhibitors
|
WO2005027921A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
|
ATE508134T1
(de)
|
2003-12-23 |
2011-05-15 |
Alchymars S P A |
Amorphe form das natriumsalzes der ibandronsäure
|
WO2005090370A1
(en)
|
2004-02-05 |
2005-09-29 |
The Regents Of The University Of California |
Pharmacologically active agents containing esterified phosphonates and methods for use thereof
|
US20050261250A1
(en)
*
|
2004-05-19 |
2005-11-24 |
Merck & Co., Inc., |
Compositions and methods for inhibiting bone resorption
|
ATE475412T1
(de)
|
2004-05-24 |
2010-08-15 |
Warner Chilcott Co Llc |
Enterische feste orale dosierform eines bisphosphonats mit einem chelate
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
MX2007000087A
(es)
*
|
2004-06-23 |
2007-11-06 |
Teva Pharma |
Acido ibandronico solido y cristalino.
|
CN101022812A
(zh)
|
2004-08-23 |
2007-08-22 |
特瓦制药工业有限公司 |
固体和晶体伊班膦酸钠及其制备方法
|
WO2008128056A1
(en)
*
|
2004-10-08 |
2008-10-23 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
|
US7358361B2
(en)
*
|
2004-10-08 |
2008-04-15 |
The Board Of Trustees Of The University Of Illinois |
Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
|
US7214818B2
(en)
*
|
2004-10-29 |
2007-05-08 |
Hoffmann-La Roche Inc. |
Method for synthesizing bisphosphonate
|
EP1832293A4
(en)
*
|
2004-12-10 |
2009-01-07 |
Tmrc Co Ltd |
MEANS FOR THE TREATMENT OF CANCER METASTAS AND CANNESMAS TREATMENT
|
CA2594802C
(en)
*
|
2005-02-01 |
2012-11-27 |
Uwe Eiermann |
Ibandronate polymorph a
|
RU2387661C2
(ru)
*
|
2005-02-01 |
2010-04-27 |
Ф.Хоффманн-Ля Рош Аг |
Полиморфная модификация в ибандроната
|
PL1855674T3
(pl)
|
2005-03-02 |
2015-01-30 |
Merck Sharp & Dohme |
Kompozycja do hamowania katepsyny K
|
US8158153B2
(en)
*
|
2005-03-17 |
2012-04-17 |
Alkermes Pharma Ireland Limited |
Nanoparticulate bisphosphonate compositions
|
EP1868628B1
(en)
|
2005-04-08 |
2014-06-11 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of poxvirus infections
|
EP2842559A3
(en)
|
2005-04-08 |
2015-03-18 |
Chimerix, Inc. |
Compounds, compositions and methods for the treatment of viral infections and other medical disorders
|
WO2007013097A1
(en)
*
|
2005-07-25 |
2007-02-01 |
Natco Pharma Limited |
Improved process for the preparation of ibandronate sodium
|
US8362086B2
(en)
|
2005-08-19 |
2013-01-29 |
Merial Limited |
Long acting injectable formulations
|
US20070049557A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Hashim Ahmed |
Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
|
WO2007074475A2
(en)
*
|
2005-12-27 |
2007-07-05 |
Natco Pharma Limited |
Novel polymorphic forms of ibandronate
|
US20070191315A1
(en)
*
|
2006-02-16 |
2007-08-16 |
Bengt Bergstrom |
Method for administering ibandronate
|
KR20080111070A
(ko)
*
|
2006-03-17 |
2008-12-22 |
더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 |
비스포스포네이트 화합물 및 방법
|
EP2038291B1
(en)
*
|
2006-06-23 |
2010-07-14 |
Cipla Limited |
Process for the synthesis of ibandronate sodium
|
US7544833B2
(en)
|
2006-09-07 |
2009-06-09 |
Hoffmann-La Roche Inc. |
Methods for producing N-(8-[2-hydroxybenzoyl]-amino) caprylic acid
|
WO2008060609A1
(en)
|
2006-11-16 |
2008-05-22 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ibandronate sodium
|
US20080139514A1
(en)
*
|
2006-11-29 |
2008-06-12 |
Subhash Pandurang Gore |
Diphosphonic acid pharmaceutical compositions
|
CA2570949A1
(en)
*
|
2006-12-12 |
2008-06-12 |
Apotex Pharmachem Inc. |
Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
|
AU2007335156A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Mylan Pharmaceuticals Ulc |
Pharmaceutical composition comprising a hot-melt granulated lubricant
|
WO2008074144A1
(en)
|
2006-12-20 |
2008-06-26 |
Genpharm Ulc |
A composition containing a bisphosphonic acid in combination with vitamin d
|
US20100144679A1
(en)
*
|
2007-03-21 |
2010-06-10 |
Duke University |
Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
|
WO2008125483A2
(en)
*
|
2007-04-11 |
2008-10-23 |
F. Hoffmann-La Roche Ag |
Multi step synthesis of ibandronate
|
AU2008240266A1
(en)
*
|
2007-04-12 |
2008-10-23 |
The Board Of Trustees Of The University Of Illinois |
Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
|
WO2008131160A1
(en)
|
2007-04-19 |
2008-10-30 |
Dr. Reddy's Laboratories Ltd. |
Ibandronate sodium polymorphs
|
WO2009020483A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ibandronate sodium
|
WO2009023866A1
(en)
|
2007-08-15 |
2009-02-19 |
Cardiodex Ltd. |
Systems and methods for puncture closure
|
US20090075944A1
(en)
*
|
2007-09-15 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched ibandronate
|
US20090099390A1
(en)
*
|
2007-09-24 |
2009-04-16 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ibandronic acid and processes for the preparation thereof
|
EP2128166A1
(en)
|
2008-05-20 |
2009-12-02 |
Chemo Ibérica, S.A. |
Polymorphic forms of Ibandronate sodium and processes for preparation thereof
|
US20090118239A1
(en)
*
|
2007-11-05 |
2009-05-07 |
Teva Pharmaceutical Industries Ltd. |
Amorphous and crystalline forms of ibandronate disodium
|
EP2234608A2
(en)
|
2007-12-11 |
2010-10-06 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
PL2222636T3
(pl)
|
2007-12-21 |
2014-04-30 |
Ligand Pharm Inc |
Selektywne modulatory receptorów androgenowych (SARM) i ich zastosowania
|
WO2009093258A2
(en)
*
|
2008-01-24 |
2009-07-30 |
Fleming Laboratories Limited |
A new and improved process for the preparation of ibandronate sodium monohydrate
|
CN105055432A
(zh)
*
|
2008-01-25 |
2015-11-18 |
奇默里克斯公司 |
治疗病毒感染的方法
|
WO2010035664A1
(ja)
*
|
2008-09-24 |
2010-04-01 |
田辺三菱製薬株式会社 |
ビスホスホン酸誘導体の製法
|
EP2180003A1
(en)
|
2008-10-21 |
2010-04-28 |
Zentiva, k.s. |
Preparation of ibandronate trisodium
|
EP2210596A1
(en)
|
2009-01-22 |
2010-07-28 |
Laboratorios Liconsa, S.A. |
Pharmaceutical composition of ibandronate sodium salt or a hydrate thereof
|
GB0906068D0
(en)
|
2009-04-07 |
2009-05-20 |
King S College London |
Bisphosphonate Compounds for chelating radionuclides
|
WO2010143193A1
(en)
|
2009-06-11 |
2010-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
WO2011011519A1
(en)
|
2009-07-21 |
2011-01-27 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
WO2011017253A1
(en)
|
2009-08-03 |
2011-02-10 |
Chimerix, Inc. |
Composition and methods of treating viral infections and viral induced tumors
|
WO2011016738A1
(en)
|
2009-08-05 |
2011-02-10 |
Zaklady Farmaceutyczne Polpharma Sa |
A process for the synthesis of 1-hydroxy-3-(n-methylpentylamino) propylidene bisphosphonic acid monosodium salt, monohydrate
|
HUE025737T2
(en)
|
2009-09-01 |
2016-05-30 |
Univ Duke |
Bisphosphonate compositions and methods for treating heart failure
|
FR2954320B1
(fr)
|
2009-12-17 |
2012-06-15 |
Cll Pharma |
Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
|
EP3216789A1
(en)
|
2010-02-12 |
2017-09-13 |
Chimerix, Inc. |
Methods of treating viral infection
|
EP2563367A4
(en)
|
2010-04-26 |
2013-12-04 |
Chimerix Inc |
METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
|
EP2609101B1
(en)
|
2010-07-14 |
2015-01-28 |
Pharmathen S.A. |
Process for the preparation of 3-(n-methyl-n-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid salt or derivatives thereof
|
TR201100151A2
(tr)
|
2011-01-06 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
İbandronate formülasyonu.
|
WO2012112363A1
(en)
|
2011-02-14 |
2012-08-23 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
EP2731591B1
(en)
|
2011-07-13 |
2020-06-17 |
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. |
Liposomes co-encapsulating a bisphosphonate and an amphipathic agent
|
CN104010647A
(zh)
|
2011-11-16 |
2014-08-27 |
杜克大学 |
用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
|
US8748097B1
(en)
|
2011-12-02 |
2014-06-10 |
President And Fellows Of Harvard College |
Identification of agents for treating calcium disorders and uses thereof
|
TR201200588A2
(tr)
|
2012-01-18 |
2012-07-23 |
Koçak Farma İlaç Ve Ki̇mya Sanayi̇ Anoni̇m Şi̇rketi̇ |
Sodyum ibandronat monohidrat polimorflarini ve polimorflu karışımlarını hazırlamak için prosesler.
|
GB201200868D0
(en)
|
2012-01-19 |
2012-02-29 |
Depuy Int Ltd |
Bone filler composition
|
CN103396332A
(zh)
*
|
2013-08-19 |
2013-11-20 |
四川协力制药有限公司 |
3—[(n—甲基—n—戊基)氨基]丙酸盐酸盐的制备方法
|
AU2014332250B2
(en)
|
2013-10-08 |
2018-07-19 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
EP3148587B1
(en)
|
2014-05-30 |
2021-02-24 |
Pfizer Inc |
Carbonitrile derivatives as selective androgen receptor modulators
|
US20210008084A1
(en)
|
2017-10-16 |
2021-01-14 |
Tsinghua University |
Mevalonate pathway inhibitor and pharmaceutical composition thereof
|
KR20200085441A
(ko)
|
2019-01-07 |
2020-07-15 |
엠에프씨 주식회사 |
이반드로네이트의 신규한 결정형 및 이의 제조방법
|
KR20220115062A
(ko)
|
2021-02-09 |
2022-08-17 |
(주)오스티오뉴로젠 |
크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|